{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:59:16Z","timestamp":1774684756944,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872078"],"award-info":[{"award-number":["81872078"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04880-y","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T15:02:01Z","timestamp":1710946921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Zhen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"4880_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"4880_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R et al (2022) Cancer incidence and mortality in China, 2016. J Natl Cancer Center 2:1\u20139. https:\/\/doi.org\/10.1016\/j.jncc.2022.02.002","journal-title":"J Natl Cancer Center"},{"key":"4880_CR3","first-page":"921","volume":"46","author":"CG Ma","year":"2008","unstructured":"Ma CG, Ye DW, Li CL, Zhou FJ, Yao XD, Zhang SL et al (2008) Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease. Zhonghua wai ke za zhi [Chin J Surg] 46:921\u2013925","journal-title":"Zhonghua wai ke za zhi [Chin J Surg]"},{"key":"4880_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238\u2013244. https:\/\/doi.org\/10.1001\/jama.294.2.238","journal-title":"JAMA"},{"key":"4880_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","volume":"77","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G et al (2020) Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol 77:365\u2013372. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.004","journal-title":"Eur Urol"},{"key":"4880_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/JU.0000000000000636","volume":"203","author":"M Marchioni","year":"2020","unstructured":"Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul AK et al (2020) New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis. J Urol 203:751\u2013759. https:\/\/doi.org\/10.1097\/JU.0000000000000636","journal-title":"J Urol"},{"key":"4880_CR7","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.Can-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A et al (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494\u20131503. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-3948","journal-title":"Cancer Res"},{"key":"4880_CR8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294\u20132303. https:\/\/doi.org\/10.1200\/JCO.20.03488","journal-title":"J Clin Oncol"},{"key":"4880_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408\u20131418. https:\/\/doi.org\/10.1056\/NEJMoa1715546","journal-title":"N Engl J Med"},{"key":"4880_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263\u2013282. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046","journal-title":"Eur Urol"},{"key":"4880_CR11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.6004\/jnccn.2022.0063","volume":"20","author":"EM Schaeffer","year":"2022","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R et al (2022) NCCN guidelines(R) insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw 20:1288\u20131298. https:\/\/doi.org\/10.6004\/jnccn.2022.0063","journal-title":"J Natl Compr Canc Netw"},{"key":"4880_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"key":"4880_CR13","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10147-022-02183-z","volume":"27","author":"Y Tohi","year":"2022","unstructured":"Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K et al (2022) Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. Int J Clin Oncol 27:1348\u20131355. https:\/\/doi.org\/10.1007\/s10147-022-02183-z","journal-title":"Int J Clin Oncol"},{"key":"4880_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/acs.chemrestox.9b00247","volume":"33","author":"C Ji","year":"2020","unstructured":"Ji C, Guha M, Zhu X, Whritenour J, Hemkens M, Tse S et al (2020) Enzalutamide and apalutamide. In vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol 33:211\u2013222. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00247","journal-title":"Chem Res Toxicol"},{"key":"4880_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","volume":"20","author":"H Uemura","year":"2020","unstructured":"Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A et al (2020) Skin rash following administration of apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol 20:139. https:\/\/doi.org\/10.1186\/s12894-020-00689-0","journal-title":"BMC Urol"},{"key":"4880_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-022-04427-1","volume":"89","author":"H T'Jollyn","year":"2022","unstructured":"T\u2019Jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP et al (2022) Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemother Pharmacol 89:629\u2013641. https:\/\/doi.org\/10.1007\/s00280-022-04427-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4880_CR17","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1158\/1078-0432.Ccr-20-1041","volume":"26","author":"C Perez-Ruixo","year":"2020","unstructured":"Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D et al (2020) Efficacy and safety exposure\u2013response relationships of apalutamide in patients with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 26:4460\u20134467. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1041","journal-title":"Clin Cancer Res"},{"key":"4880_CR18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/iju.14860","volume":"29","author":"D Sasaki","year":"2022","unstructured":"Sasaki D, Hatakeyama S, Tanaka T, Okamoto T, Yoneyama T, Ohyama C (2022) Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: a multicenter retrospective study. Int J Urol 29:772\u2013773. https:\/\/doi.org\/10.1111\/iju.14860","journal-title":"Int J Urol"},{"key":"4880_CR19","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.21873\/anticanres.15682","volume":"42","author":"M Katsuta","year":"2022","unstructured":"Katsuta M, Kimura T, Tashiro K, Murakami M, Hata K, Yanagisawa T et al (2022) Low body weight as a risk factor for apalutamide-related cutaneous adverse events. Anticancer Res 42:2023\u20132028. https:\/\/doi.org\/10.21873\/anticanres.15682","journal-title":"Anticancer Res"},{"key":"4880_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1097\/JU.0000000000002425","volume":"207","author":"A Pan","year":"2022","unstructured":"Pan A, Reingold RE, Zhao JL, Moy A, Kraehenbuehl L, Dranitsaris G et al (2022) Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide. J Urol 207:1010\u20131019. https:\/\/doi.org\/10.1097\/JU.0000000000002425","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04880-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:23:53Z","timestamp":1735853033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04880-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4880"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04880-y","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Second Hospital of Tianjin Medical University. All patients received informed consent regarding this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"171"}}